 |
|
 |
William T. Bellamy, RPh, PhD
Director, Molecular Pathology
Associate Professor of Pathology
|
PhD
Pharmacology and Toxicology Department
University of Arizona, College of Pharmacy
Post Doctoral Training
Department of Molecular Biology
Arizona Cancer Center
Major Interests
Molecular diagnostics, Hematopathology
Research Interests
Multiple Myeloma; Myelodyslastic syndromes; Non-hodgkins lymphomas; Expression of angiogenic factors in hematopoietic neoplasms; Antineoplastic drug resistance
Email: wbellamy@uams.edu
|
| Selected Publications |
| Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl M, Staudt LM. Frequent engagement of the classical and alternative NF-kB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115-130, 2007. Giles FJ, Bellamy WT, Estrov Z, O’brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Stienfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or Myelodysplastic syndrome (MDS). Leukemia Research 30:801-811, 2006. Baker AF, Bellamy WT, Tate WR, Bair WB, Heaton R, List AF. Suppressor of cytokine signaling-3 (SOCS-3) is over-expressed in erythroid precursors of Myelodysplastic syndrome. Leukemia. 20:1620-1621, 2006. List AF, Baker AF, Green S, Bellamy WT. Lenalidomide: Targeted anemia therapy for Myelodysplastic syndromes. Cancer Control, 13 (supplement):4-11, 2006. List AF, Glinsmann-Gibson B Stadheim C, Meuillet E, Bellamy W, Powis G. VEGFR1 and VEGFR2 ligation stimulate phosphoinositide-3-kinase dependent Akt activation and promote proliferation of AML cells. Experimental Hematology 32:526-535, 2004. |
| Abstracts |
| Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive NHL: correlative studies from SWOG S0108 trial. Stopeck A, Iannone M, Rimsza L, Miller T, Fisher R, and Bellamy WT. Blood 104:629a, 2004. Somlo G, Bellamy WT, Zimmerman TM, Frankel P, Tuscano J, O’Donnell M, Morbacher A, Forman S, Chen H, Doroshow J, Gandara D. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma. Blood 106: 723a 2005. Sharma S, Sawyer J, Bellamy WT, Lorsbach R, Oza K, Singh ZN. Morphological spectrum of non-Burkitt lymphomas with MYC-associated abnormalities. Arch Pathol Lab Med 132: 1465, 2008. Santra M, Shaughnessy J, Williams DR, Barlogie B, Bellamy WT. Expression of myeloma-specific markers in bone marrow spicules using a novel immunohistochemical technique. Blood 112: 5152a, 2008. |
UAMS
Department of Pathology
4301 West Markham #517
Little Rock AR 72205
501-686-5170
Bruce Smoller, M.D., Chair
For general information or questions about the Department of Pathology
you may contact Linda DePriest, Executive Assistant to the Department Chair. For web page issues you may contact the
. |
|
 |
